Orphan Drug Designation Granted to Investigational Gene Therapy for Rare Form of Muscular Dystrophy

Submitted by admin on January 2, 2019 - 10:08am

Source:

CP Wire

News Tags:

Limb Girdle Muscular Dystrophy

muscular dystrophy

FDA

Myonexus

NYO-102

gene therapy

Headline:

Orphan Drug Designation Granted to Investigational Gene Therapy for Rare Form of Muscular Dystrophy

snippet:

Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for MYO-102, a novel gene therapy candidate for alpha-sarcoglycanopathy, also known as Limb Girdle Muscular Dystrophy Type 2D (LGMD2D).

Search form

You are here

Orphan Drug Designation Granted to Investigational Gene Therapy for Rare Form of Muscular Dystrophy

Orphan Drug Designation Granted to Investigational Gene Therapy for Rare Form of Muscular Dystrophy